11/2/2010

Discovery Laboratories has obtained drug-orphan designation from the FDA for aerosolized KL4 surfactant, an experimental treatment for cystic fibrosis. In October, the biotech firm said the drug appeared safe and well-tolerated in a Phase II study.

Full Story:
Reuters

Related Summaries